 |
Introduction |
The androgen insensitivity syndromes (AIS) arise from target
tissue resistance to androgen action caused by molecular abnormalities in the X chromosome linked androgen receptor (AR) gene. The clinical manifestations of androgen resistance vary from external genitalia that
are completely female (complete AIS) to degrees of partial masculinisation (partial AIS). These syndromes are probably the most
common identifiable cause of male under-masculinisation and consequent
genital ambiguity at birth, but can be confused with other causes of
under-masculinisation if not investigated adequately.1 Diagnostic schema for studying possible cases of AIS have been proposed,1-3 but diagnosis in the absence of binding
studies of AR and mutational analysis of the gene encoding AR remains difficult. Age related reference ranges for serum gonadotrophins and
testosterone are available4-6 and, although these
measurements are often performed at the time of presentation, there is
some uncertainty regarding the value of these tests. Postpubertal
patients with complete AIS, who have testes in situ, have raised serum concentrations of luteinising hormone (LH), and normal to slightly raised concentrations of follicle stimulating hormone (FSH) and testosterone relative to normal boys.7 8 In contrast,
affected prepubertal children have LH and testosterone concentrations
in the normal range.8 However, studies in infants and
neonates with AIS are restricted to a few case
reports,9-11 where it is debatable whether LH and
testosterone concentrations were abnormal, considering the variable
pattern of these hormones in normal infants.5 The
stimulation of testosterone production by human chorionic gonadotrophin
(hCG) has traditionally been performed to detect functioning testicular
tissue,12-14 as well as to pinpoint abnormalities in
testosterone biosynthesis.15 16 Case reports as well as a
recent series of nine cases of AIS show that testosterone increases significantly after hCG stimulation.9-12 Therefore, we
have collected information about the gonadotrophin-gonadal axis in a
group of patients with complete and partial AIS with abnormal AR
binding and/or mutations in the AR gene. This information should
improve the interpretation of investigations performed commonly in
cases of male under-masculinisation.
 |
Patients and methods |
The UK database of ambiguous genitalia and intersex disorders,
which is held at Cambridge, has over 700 separate entries. Among these,
there are 255 cases of AIS diagnosed by clinicians nationwide, of whom
phenotype is compatible with complete AIS in 102 and partial AIS in
153. We obtained clinical information and results of the investigations
performed. For our study, patients were only selected if there was
evidence of AR dysfunction (AR +ve)
that is, abnormalities on
mutational analysis of the gene encoding AR and/or abnormal results
from an AR binding assay, as described previously.17 18
For the analysis, these cases of complete AIS and partial AIS were
considered as one group, but were divided into three subsets according
to age as follows: infants, less than 1 year old; children, 1-13 years
old; postpubertal, more than 13 years old. Cases where investigations
were performed after gonadectomy were excluded. Data analysed included
age at investigation, gestation, dose of hCG stimulation, dose of LH releasing hormone (LHRH), serum testosterone (nmol/l),
dihydrotestosterone (DHT; nmol/l), LH (U/l), and FSH (U/l). As shown in
fig 1, the results of these tests were available in a variable number
of cases of AIS. Hormonal analyses were performed by standard
immunoassays at endocrine laboratories participating in a national
external quality control service (UKNEQAS). The interassay variability ranges between 10% and 20% (by courtesy of UKNEQAS). Assay results are presented as medians and 90th centiles, and intergroup comparison was performed by the Wilcoxon signed rank (WSR) test. Chi-squared analysis was used to evaluate any relation between clinical features and the hCG test. Testosterone, LH, and FSH values were compared with
those described in normal children in the
literature.4

View larger version (24K):
[in this window]
[in a new window]
|
Figure 1
Complete AIS (CAIS) and partial AIS (PAIS) cases in
the database at the time of our study and the subset of cases with
abnormalities of AR binding or AR gene mutations (AR +ve; shaded bars)
where information regarding basal plasma testosterone, hCG stimulation
test, basal serum gonadotrophins (LH and FSH), and gonadotrophin
releasing hormone stimulation test (GnRH) were available.
|
|
 |
Results |
TESTOSTERONE AND hCG STIMULATION
Basal testosterone concentrations were available in 58 AR +ve
cases and were high in infancy, declining to low during childhood, before rising again postpubertally (fig 2A). There was considerable variation in testosterone concentrations over the 1st year consistent with the changes described in healthy boys over the first 6 months of
life (fig 2B). Twenty three of 30 measurements were within the
historical reference range, whereas seven of 30 were above this
range.

View larger version (13K):
[in this window]
[in a new window]
|
Figure 2
Basal plasma testosterone concentrations in AIS. (A)
Total AR +ve cases of AIS (the high testosterone concentrations in
three patients are plotted separately). (B) All AR +ve cases less
than 1 year old. Closed circles and crosses represent cases of complete
AIS and partial AIS, respectively. The shaded area represents the
normal reference range.4
|
|
There was considerable variation in the regimen of hCG stimulation
used, although 1000-2000 U for three consecutive days accounted for
59% of all the tests (fig 3). Results of hCG stimulation were available for 45 patients with AR dysfunction (fig 1) and the median
(10-90th centile) rise in testosterone on hCG stimulation in these
cases was 9.5 (1.8-38) times the basal concentration. The testosterone
increment was not related to the total hCG dose, the age at which the
test was performed, or the basal concentration of testosterone. The
actual concentrations of testosterone are shown in fig 4. Twenty three
hCG stimulation tests were performed in infants and 21 were performed
in older children. The median (10-90th centile) basal and peak
testosterone values were 2.3 nmol/l (0.5-9.5) and 14.8 nmol/l
(3.8-34.4), respectively, in the infants, and 0.8 nmol/l (0.2-5.1)
and 10.6 nmol/l (3.9-21.7), respectively, in the older children.
There was no significant difference between the basal or peak values in
the infants and older children. Among the cohort which had an hCG
stimulation test, there were 12 patients who had testes that were
bilaterally descended and nine where they were bilaterally
intra-abdominal; the remainder had a combination of these features. The
median (10-90th centile) testosterone increment on hCG stimulation was 5 (1.7-88.9) times the basal value and 9.5 (1.9-53) times the basal
value (not significant) in the two groups,
respectively.

View larger version (10K):
[in this window]
[in a new window]
|
Figure 3
Frequency (n) of different regimens of HCG stimulation
tests used in all cases of suspected AIS.
|
|

View larger version (16K):
[in this window]
[in a new window]
|
Figure 4
Increment in baseline plasma testosterone values (pre)
following hCG stimulation (post) in AR +ve cases of complete AIS (CAIS)
and partial AIS (PAIS).
|
|
DHT AND hCG STIMULATION
Baseline and post-hCG stimulation DHT concentrationss were
available in 30 and 23 AR +ve cases of AIS, respectively (fig 1). In
the latter group of cases mean (10-90th centile) increment in
testosterone on hCG stimulation was 5.5-fold (2-63) and the median
(10-90th centile) increment in DHT was 2.2-fold (1.3-13.2). The dose
of hCG used was known in 21 of 23 cases; there was no relation between
the dose and the rise in testosterone or DHT. The median (10-90th
centile) basal testosterone:DHT (T:DHT) ratio at 2.5 (0.6-11) was
lower than the median (10-90th centile) stimulated T:DHT ratio of 6.1 (1.3-17; p = 0.0009). Figure 5 shows the variation in the T:DHT
ratio in children under the age of 3 years (n = 20). Following hCG
stimulation an age dependent rise in the ratio was noticed over the 1st
year of life.

View larger version (10K):
[in this window]
[in a new window]
|
Figure 5
Plasma T:DHT ratio in children less than 3 years of
age before (pre) and after (post) hCG stimulation.
|
|
GONADOTROPHINS AND LHRH STIMULATION
Basal LH and FSH values were available for 42 AR +ve cases of AIS
(fig 1), which showed that age dependent variation was high in the 1st
few months of life, reaching a nadir in childhood, before rising again
(fig 6). Seventeen of 18 FSH measurements and 11 of 19 LH measurements
performed in the 1st year of life were within age related ranges (fig
7), and seven LH measurements were above the reference range. The
median basal and stimulated concentrations of LH and FSH are shown in
table 1. Exaggerated responses to LHRH stimulation were seen in the
infants and the postpubertal group. Although the peak FSH value in the
children was not exaggerated, the median peak LH value was six times
higher than basal
values.

View larger version (18K):
[in this window]
[in a new window]
|
Figure 6
Basal serum LH and FSH concentrations in all AR +ve
cases of AIS. Very high concentrationss in two patients are plotted
separately.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
Figure 7
Basal LH and FSH concentrations in infants with AIS
during the 1st year of life. The shaded area represents the normal
reference range.4
|
|
View this table:
[in this window]
[in a new window]
|
Table 1
Median (range) basal and peak serum
LH and FSH concentrations in cases with AR/AB +ve AIS who had an LHRH
stimulation test
|
|
 |
Discussion |
The diagnosis of androgen insensitivity can be difficult to
establish but is facilitated by a family history showing X linked inheritance, a comprehensive clinical examination, and investigations to exclude other causes of male under-masculinisation. Published studies of biochemical investigations, including gonadotrophin and
androgen values, have concentrated on older children and adults; most
of these studies lack information about AR binding and mutational analysis of the AR gene. Serum gonadotrophin as well as
testosterone concentrations are often measured when AIS is suspected;
however, adequate interpretation of the results has been restricted
because of different opinions based on personal observations as well as on case studies.9-11 19 20 Therefore, we analysed
biochemical data collected through the UK ambiguous genitalia and
intersex database on cases proved to have AR dysfunction because of
abnormal AR binding and/or AR gene mutation. Because the molecular
defect has the same basis, cases of complete AIS and partial AIS were studied as one group. The nature of the resource meant that there were
no control data for each case, so we have relied on historical data
gathered by Andersson et al and Winter
et al.4-6 This reference range
compares very well with that published by Forest et
al.21 A register based study has the problem of
data reporting from multiple and variable sources. Nevertheless, we
believe this was more than offset by the large number of cases of AIS
in which the tests had been performed and reported. Although assays
were performed in a number of laboratories, each was a participant in a
national external quality control service.
There were a number of patients with suspected AIS in whom basal
testosterone values and results of hCG stimulation tests were
unavailable. The reason may just be incomplete data retrieval, but it
is also possible that in some patients the tests were not performed.
This occurred more often in complete AIS where the diagnosis seems to
be more clear cut. However, confusion can occur with other causes of
male under-masculinisation where the phenotype may be unambiguously
female such as in Leydig cell hypoplasia, 5
-reductase deficiency,
and 17
-hydroxysteroid dehydrogenase deficiency.
The analysis indicates that hCG and LHRH stimulation tests as well as
measurement of basal concentration of gonadotrophins and testosterone
are performed often but not always in suspected cases of AIS. The dose
of hCG varied considerably between and within centres; similar
information about the LHRH stimulation test was not available. A single
dose of hCG can sufficiently stimulate testosterone production in most
cases22 and there is a need to standardise this test.
However, the lack of a relation between total hCG dose and testosterone
increment suggests that the dose is probably not that crucial; this
method of analysis does not take account of the influence of repetitive
stimulation delivered by multiple hCG injections.
During childhood, testosterone was mostly within normal reference
ranges. The concentrations were abnormally high in some cases at the
time of the postnatal surge, a phenomenon observed in normal boys
between 2 and 6 months of age.5 The magnitude of this
surge is highly variable in normals, as was seen in those with AIS in
our study. Normally, sex hormone binding globulin (SHBG) concentrations
show a parallel rise with testosterone during the surge of early
infancy and the ratio of testosterone to SHBG, the free androgen index,
does not change remarkably.23 However, administration of
exogenous testosterone results in a fall in SHBG
concentrations24 and this response has been shown to be absent in patients with AIS.25 26 It is possible that
changes in the free androgen index during the postnatal surge in
testosterone have a characteristic pattern in AIS. Salivary
testosterone concentrations, which reflect the non-protein bound
fractions of total testosterone,27 might prove to be a
non-invasive method of assessing these changes. Serum testosterone
concentrations increased in all cases following hCG stimulation,
although the increment was variable. In general, at least a twofold to
threefold increase in testosterone is considered to be
normal13 28; a number of children in our study, with proved AR dysfunction, had a testosterone increment less than twofold.
An inadequate rise in testosterone on hCG stimulation in patients with
male under-masculinisation suggests a defect of testosterone
biosynthesis; our study indicates that in such cases AR abnormalities
still need to be considered. Previous studies suggest that the SHBG
decrement following hCG stimulation should be insignificant in those
cases where there is only a minimal rise in
testosterone.25 An additional marker following hCG
stimulation tests in cases of male under-masculinisation is an
evaluation of phallic growth as a clinical index of androgen
responsiveness.29
The plasma testosterone response to hCG stimulation has been reported
to be lower in cryptorchid boys compared with normal boys.12 We found no difference in response between
children with bilateral scrotal and bilateral abdominal testes. No
instances of testicular dysgenesis were reported in cases where
testicular histology was performed (data not shown). The lower response
in previous studies probably reflects the existence of a primary testicular abnormality underlying the cryptorchidism.
Baseline and post-hCG measurements of DHT were not often performed. The
baseline T:DHT ratio in patients in whom these measurements were
performed was within the range 1.5-17 reported in normal male infants
by Pang et al.30 Our finding of
a significant increase in the ratio following hCG stimulation does not
concur with their observations in healthy infants, whereas the values
were similar to those reported in healthy infants by Forest
et al, which ranged between 6 and
16.8.21 An increase in the T:DHT ratio with age in this
group of patients with AIS suggests an age dependent decrease in
5
-reductase activity, similar to that reported for normal children.30 One neonate with a clinical phenotype
consistent with complete AIS and defective androgen binding had a T:DHT
ratio of 25.8. This might be an example of AIS with a secondary
5
-reductase deficiency,31 but the precise diagnosis
awaits mutational analysis of the genes encoding both 5
-reductase
and AR. Our findings also suggest that the post-hCG stimulation T:DHT
ratio may overlap with values expected in cases of 5
-reductase
deficiency, resulting in the likelihood of false positive cases. It is
possible that the measurement of the urinary
tetrahydrocortisol:allotetrahydrocortisol ratio might be a more
specific indicator of 5
-reductase deficiency than the T:DHT
ratio.32
Basal LH but not FSH values were often above the historical reference
range and the pattern of variation was similar to that seen for
testosterone. In a number of cases, however, LH was not greatly raised,
indicating that a high basal LH value is not a universal finding in
AIS. The surge in LH, which is also described in healthy
infants,5 was accompanied during the first year by an
exaggerated LH rise following LHRH stimulation. There was also an
exaggerated FSH response in infancy but, unlike LH, this was not
sustained in later childhood. These data support a direct role for
androgen in controlling LH release.33-35
Our study provides data to help with the interpretation of
investigations performed to evaluate the gonadotrophin-gonadal axis in
cases of suspected AIS. Although a positive hCG stimulation test
excludes biosynthetic defects of testosterone, an inadequate testosterone response does not necessarily exclude AIS. Basal LH and
testosterone values are highly variable and might not be increased
during early infancy. An LHRH stimulation test might be useful to
evaluate cases of suspected AIS presenting in mid-childhood. Evaluation
of the pituitary-gonadal axis in the under-masculinised child using
uniform protocols should be more routine if the diagnostic yield in AIS
and related phenotypes is to be improved.
The support of numerous clinicians in the UK and the European
mainland who have contributed cases to the database is gratefully appreciated. We thank Mrs N Coggins for maintaining the database, and L
Dovey, Z Rasekh, and J Rowland for technical assistance. Currently, SFA
has support from the Sir Halley Stewart trust. Grant support was
received from the Birth Defects Foundation and the European Union
Biomed programme, the Medical Research Council, and the Wellcome Trust.
Presented in part at the 25th annual meeting of the British Society of
Paediatric Endocrinology and Diabetes at the Royal Society of Medicine,
London, UK.
| 1.
|
Hughes IA,
Williams DM,
Batch JA,
Patterson MN. Male pseudohermaphroditism: clinical management, diagnosis and treatment.
Horm Res
1993;38:77-81.
|
| 2.
|
Berkovitz GD,
Lee PA,
Brown TR,
Migeon CJ. Etiologic evaluation of male pseudohermaphroditism in infancy and childhood.
Am J Dis Child
1984;138:775[Abstract/Free Full Text]..
|
| 3.
|
Viner RM,
Teoh Y,
Williams DM,
Patterson MN,
Hughes IA. Androgen insenstivity syndrome: a survey of diagnostic procedures and management in the UK.
Arch Dis Child
1997;77:305-309[Abstract/Free Full Text].
|
| 4.
|
Andersson A-M,
Toppari J,
Haavisto A-M,
et al. Longitudinal reproductive hormone profiles in infants: peak of inhibin B levels in infant boys exceeds levels in adult men.
J Clin Endocrinol Metab
1998;83:675-681[Abstract/Free Full Text].
|
| 5.
|
Winter JSD,
Faiman C,
Hobson WC,
Prasad AV,
Reyes FI. Pituitary-gonadal relations in infancy: 1. Patterns of serum gonadotrophin concentrations from birth to four years of age in man and chimpanzee.
J Clin Endocrinol Metab
1975;40:545-551[Abstract/Free Full Text].
|
| 6.
|
Winter JSD,
Hughes IA,
Reyes FI,
Faiman C. Pituitary-gonadal relations in infancy: 2. Patterns of serum gonadal steroid concentrations in man from birth to two years of age.
J Clin Endocrinol Metab
1976;42:679-686[Abstract/Free Full Text].
|
| 7.
|
Morris JM,
Mahesh VB. Further observations on the syndrome, "testicular feminisation".
Am J Obstet Gynecol
1963;87:731-748.
|
| 8.
|
Tremblay RR,
Foley TP,
Corvol P,
et al. Plasma concentration of testosterone, dihydrotestosterone, testosterone-oestradiol binding globulin, and pituitary gonadotrophins in the syndrome of male pseudohermaphroditism with testicular feminisation.
Acta Endocrinol
1972;70:331-341.
|
| 9.
|
Lee PA,
Brown TR,
LaTorre HA. Diagnosis of the partial androgen insensitivity chorionic-gonadotrophin stimulation tests in prepubertal and early pubertal boys.
Eur J Paediatr
1986;154:890-892.
|
| 10.
|
Nagel RA,
Lippe BM,
Griffin JE. Androgen resistance in the neonate: use of hormones of the hypothalamic-pituitary-gonadal axis for diagnosis.
J Pediatr
1986;109:486-488[Medline].
|
| 11.
|
Isurugi K,
Hasegawa F,
Shibahara N,
et al. Incomplete testicular feminisation syndrome studies on androgen receptor (AR) function, AR gene analysis, and aromatase activities at puberty and long-term observations of clinical and hormonal features from infancy to puberty.
Endocr J
1996;43:557-564[Medline].
|
| 12.
|
Grant DB,
Laurance BM,
Atherden SM,
Ryness J. HCG stimulation test in children with abnormal sexual development.
Arch Dis Child
1976;51:596-601[Abstract/Free Full Text].
|
| 13.
|
Davenport M,
Brain C,
Vandenberg C,
et al. The use of the HCG stimulation test in the endocrine evaluation of cryptorchidism.
Br J Urol
1995;76:790-794[Medline].
|
| 14.
|
Urban MD,
Lee PA,
Lanes R,
Migeon CJ. HCG stimulation test in children with cryptorchidism.
Clin Pediatr
1986;26:512-514.
|
| 15.
|
Balducci R,
Ghirri P,
Brown TR,
et al. A clinician looks at androgen resistance.
Steroids
1996;61:205-211[Medline].
|
| 16.
|
Rosenfeld RL,
Barmach de Niepomniszsze,
Kenney FM,
Genel M. The response to human chorionic gonadotrophin administration in boys with and without 5-3 -hydroxysteroid dehydrogenase deficiency.
J Clin Endocrinol Metab
1974;39:370-374[Abstract/Free Full Text].
|
| 17.
|
Batch JA,
Williams DM,
Davies HR,
et al. Androgen receptor gene mutations identified by SSCP in fourteen subjects with androgen insensitivity syndrome.
Hum Mol Genet
1992;1:497-503[Abstract/Free Full Text].
|
| 18.
|
Hughes IA,
Evans BAJ. The fibroblast as a model for androgen resistant states.
Clin Endocrinol
1988;28:565-569[Medline].
|
| 19.
|
Quigley CA,
De Bellis A,
Marschke KB,
El-Awady MK,
Wilson EM,
French FS. Androgen receptor defects: historical, clinical, and molecular perspectives.
Endocr Rev
1995;16:271-321[Abstract/Free Full Text].
|
| 20.
|
Forest MG,
Mollard P,
David M,
Morel Y,
Bertrand J. Syndrome d'insensibilite incomplete aux androgenes.
Arch Fr Paediatr
1990;47:107-113.
|
| 21.
|
Forest MG,
De Peveretti E,
Bertrand J. Testicular and adrenal androgens and their binding to plasma proteins in the perinatal period: developmental patterns of plasma testosterone, 4-androstenedione, dehydroepiandrosterone and its sulfate in premature and small for date infants as compared with that of full term infants.
J Steroid Biochem
1980;12:25-36[Medline].
|
| 22.
|
Kauchansky A,
Frydman M,
Nussinovitch M,
Varsano I. Evaluation of human chorionic-gonadotrophin stimulation tests in prepubertal and early pubertal boys.
Eur J Paediatr
1995;154:890-892[Medline].
|
| 23.
|
Bolton NJ,
Tapanainen J,
Koivisto M,
Vihko R. Circulating sex hormone binding globulin and testosterone in newborns and infants.
Clin Endocrinol
1989;31:201-207[Medline].
|
| 24.
|
Belgoroski A,
Rivarola MA. Sex-hormone binding globulin response to testosterone. An androgen sensitivity test.
Acta Endocrinol
1985;109:130-138.
|
| 25.
|
Bertelloni S,
Federico G,
Baroncelli GI,
et al. Biochemical selection of prepubertal patients with androgen insensitivity syndrome by sex hormone-binding globulin response to the human chorionic gonadotrophin test.
Pediatr Res
1997;41:266-271[Medline].
|
| 26.
|
Sinnecker GHG,
Hiort O,
Nitsche PM,
Kruse K. Functional assessment and clinical classification of androgen sensitivity in patients with mutations of androgen receptor gene.
Eur J Pediatr
1995;156:7-14.
|
| 27.
|
Huhtaniemi I,
Dunkel L,
Perheentupa J. Transient increase in postnatal testicular activity is not revealed by longitudinal measurements of salivary testosterone.
Pediatr Res
1986;20:1324-1327[Medline].
|
| 28.
|
Walker JM,
Hughes IA. Tests and normal values in paediatric endocrinology.
In:
Brook CGD,
ed.
Clinical paediatric endocrinology. Oxford: Blackwell Science Ltd, 1995;782.
|
| 29.
|
Almaguer MC,
Saenger P,
Linder BL. Phallic growth after HCG a clinical index of androgen responsiveness.
Clin Pediatr
1993;32:329-333.
|
| 30.
|
Pang S,
Levine LS,
Chow D,
Sagian F,
Saenger P,
New MI. Dihydrotestosterone and its relationship to testosterone in infancy and childhood.
J Clin Endocrinol Metab
1985;48:821-826[Abstract/Free Full Text].
|
| 31.
|
Imperato-McGinley J,
Peterson RE,
Gautier T,
et al. Hormonal evaluation of a large kindred with complete androgen insensitivity: evidence for secondary 5 -reductase deficiency.
J Clin Endocrinol Metab
1982;54:931-941[Abstract/Free Full Text].
|
| 32.
|
Odame I,
Donaldson MDC,
Wallace AM,
Cochran M,
Smith PJ. Early diagnosis and management of 5-alpha-reductase deficiency.
Arch Dis Child
1992;67:720-723[Abstract/Free Full Text].
|
| 33.
|
Bagatell CJ,
Dahl KD,
Bremner WJ. The direct pituitary effect of testosterone to inhibit gonadotropin secretion in men is partially mediated by aromatization to estradiol.
J Androl
1994;15:15-21[Abstract/Free Full Text].
|
| 34.
|
Shecker CB,
Matsumoto AM,
Bremner WJ. Testosterone administration inhibits gonadotropin secretion by an effect directly on the human pituitary.
J Clin Endocrinol Metab
1989;68:397-401[Abstract/Free Full Text].
|
| 35.
|
Zarate A,
Canales SE,
Soria J,
Carballo O. Studies on the luteinizing hormone and follicle-stimulating hormone-releasing mechanism in the testicular feminization syndrome.
Am J Obstet Gynecol
1974;119:971-977[Medline].
|